Lipocine director John W. Higuchi buys 25,007 shares

Lipocine Inc. director John W. Higuchi reported two direct purchases of common stock, totaling 25,007 shares.

Rhea-AI Filing Summary

Lipocine Inc. director John W. Higuchi reported two direct purchases of common stock, totaling 25,007 shares. He bought 9,037 shares at $2.15 per share on September 29, 2026, and 15,970 shares at $2.23 per share on September 30, 2026. No Rule 10b5-1 plan is reported for these purchases.

Insider Trade Summary

Net Buyer: 25,007 shares

Net Buy 2 txns

Insider Higuchi John W.

Role Director

Bought 25,007 shs ($55K)

Type	Security	Shares	Price	Value
Purchase	Common stock	15,970	$2.23	$36K
Purchase	Common stock	9,037	$2.15	$19K

Holdings After Transaction: Common stock — 241,365 shares (Direct)

Key Figures

Shares purchased: 9,037 shares Price per share: $2.15 Shares purchased: 15,970 shares +2 more

5 metrics

Shares purchased 9,037 shares Direct purchase on September 29, 2026

Price per share $2.15 Direct purchase on September 29, 2026

Shares purchased 15,970 shares Direct purchase on September 30, 2026

Price per share $2.23 Direct purchase on September 30, 2026

Shares purchased 25,007 shares Total across the two reported purchases

Key Terms

Rule 10b5-1 plan, Non-derivative

2 terms

Rule 10b5-1 plan regulatory

"No Rule 10b5-1 plan is reported for these purchases."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Non-derivative financial

"non-derivative transaction in common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LPCN shares did John W. Higuchi buy?

John W. Higuchi bought 25,007 shares across two reported purchases: 9,037 shares at $2.15 per share on September 29, 2026, and 15,970 shares at $2.23 per share on September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 08:28 PM Accepted by SEC EDGAR 10/01/2026 - 08:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higuchi John W.

(Last) (First) (Middle)

C/O 675 ARAPEEN DR

SUITE 202

(Street)

SALT LAKE CITY UTAH 84108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	09/29/2026	09/29/2026	P		9,037	A	$2.15	225,395	D
Common stock	09/30/2026	09/30/2026	P		15,970	A	$2.23	241,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/John W. Higuchi	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)